The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

BACKGROUND: The dipeptidyl peptidase-4 inhibitor sitagliptin, a new anti-diabetic medicine, is effective in treating type 2 diabetes mellitus by increasing the activation and duration of action of glucagon-like peptide-1. Since atherosclerosis is the main pathological feature of diabetic cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yanmei, Li, Chenzhong, Guan, Meiping, Zheng, Zongji, Li, Jingjing, Xu, Wenwei, Wang, Ling, He, Feiying, Xue, Yaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916068/
https://www.ncbi.nlm.nih.gov/pubmed/24490809
http://dx.doi.org/10.1186/1475-2840-13-32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916068/
https://www.ncbi.nlm.nih.gov/pubmed/24490809
http://dx.doi.org/10.1186/1475-2840-13-32

Ejemplares similares